How has the acquisition of Bioneeds , a pre-clinical CRO in 2021 and Heads , a European CRO in 2024 benefited the company ? What is the long-term objective and are there more such acquisitions in the pipeline ?
The acquisitions of Bioneeds in 2021 and Heads in 2024 have significantly bolstered Veeda Clinical Research ’ s capabilities and market position .
The acquisition of Bioneeds allowed Veeda to extend its services from clinical research to preclinical research , offering a comprehensive range of services from drug discovery to clinical development . Bioneeds brought in expertise in toxicology , pharmacology , and other preclinical services , enhancing Veeda ’ s overall capabilities . This acquisition enabled Veeda to provide integrated solutions to its clients , covering the entire spectrum of drug development .
The acquisition of Heads , a European CRO , expanded Veeda ’ s global footprint , allowing it to conduct clinical trials across Europe , North America , South America , and the Asia Pacific region . Heads brought in strong expertise in late-stage clinical trials , particularly in oncology , which complemented Veeda ’ s existing capabilities . With Heads ’ operational presence in multiple geographies , Veeda gained access to a diverse patient population , facilitating largescale , multi-geography trials .
These strategic acquisitions have positioned Veeda as a leading global CRO with comprehensive capabilities ,
BioTech
BIOVOICENEWS . COM 27